Complex Regional Pain Syndrome (CRPS) After an Accident: Medications and Pharmacy Liens

James Wong — Founder & Pharmacist, LienScripts | February 12, 2026 | 9 min read

CRPS is one of the most severe and medication-intensive conditions arising from personal injury accidents. This guide covers the Budapest diagnostic criteria, complex medication protocol, and why pharmacy liens are often the only way patients access these specialty treatments.

What Is Complex Regional Pain Syndrome?

Complex Regional Pain Syndrome (CRPS) is a chronic neuropathic pain condition characterized by severe, disproportionate pain in a limb following tissue injury, surgery, or nerve damage. It is one of the most painful and debilitating conditions recognized in medicine, and one of the most challenging to treat.

CRPS is classified into two types. CRPS Type I (formerly called reflex sympathetic dystrophy, or RSD) develops without a confirmed nerve injury -- it typically follows soft-tissue trauma, fractures, or surgery. CRPS Type II (formerly called causalgia) develops in association with a confirmed nerve lesion. Despite different precipitating mechanisms, both types share the same clinical features, diagnostic criteria, and treatment approaches.

In personal injury practice, CRPS Type I is the more commonly encountered form. It can develop after car accidents, slip-and-fall injuries, sports injuries, and workplace accidents -- and its emergence following a relatively minor-appearing traumatic event is a medically well-recognized phenomenon that attorneys must be prepared to document and explain.

[!KEY] CRPS is recognized by the International Association for the Study of Pain (IASP) as a distinct clinical syndrome. Its presence in a PI case dramatically increases the complexity of treatment and the long-term care requirements -- both of which are reflected in an extended pharmacy lien record spanning months to years.

The Budapest Criteria: Diagnosing CRPS

CRPS diagnosis is clinical -- there is no definitive blood test or imaging finding that confirms the diagnosis. The internationally accepted diagnostic standard is the Budapest Criteria, developed at a 2003 consensus workshop and subsequently validated by Harden and colleagues.

The Budapest Criteria require all four of the following:

1. Continuing pain disproportionate to any inciting event
2. At least one symptom in three of the following four categories: sensory (hyperalgesia or allodynia); vasomotor (temperature asymmetry, skin color changes); sudomotor/edema (sweating changes, edema); motor/trophic (decreased range of motion, weakness, tremor, hair/nail/skin changes)
3. At least one sign in two of the four categories above, confirmed on physical examination
4. No other diagnosis better explains the signs and symptoms

The Budapest Criteria are important in PI litigation because they provide an objective, internationally recognized diagnostic framework that treating physicians, IME doctors, and expert witnesses must engage with. A CRPS diagnosis supported by careful Budapest Criteria documentation is substantially more defensible than a vague diagnosis of RSD or chronic pain.

[!SOURCE] Harden RN, et al. "Validation of proposed diagnostic criteria (the Budapest Criteria) for complex regional pain syndrome." Pain. 2010;150(2):268-274. PMID: 20493633. This study validated the Budapest Criteria in a multi-site sample, demonstrating 70% sensitivity and 94% specificity. https://pubmed.ncbi.nlm.nih.gov/20493633/

How CRPS Develops After Personal Injury

CRPS does not develop in all trauma patients -- its pathophysiology involves a complex interplay of peripheral sensitization, central sensitization, autonomic nervous system dysregulation, and neuroinflammation that is not yet fully understood. What is known is that CRPS can emerge after injuries of varying severity, and that the intensity of the initial trauma does not predict who will develop CRPS.

Common PI injury mechanisms that precipitate CRPS include:

• Wrist and hand injuries: Colles fractures, wrist sprains, and crush injuries are among the most common precipitants of upper extremity CRPS Type I
• Foot and ankle injuries: Ankle fractures, sprains, and post-surgical complications frequently trigger lower extremity CRPS
• Knee injuries: Post-surgical or post-traumatic knee CRPS can produce severe disabling pain disproportionate to the structural injury
• Shoulder injuries: SLAP tears, rotator cuff injuries, and shoulder surgery can trigger shoulder-girdle CRPS with spreading symptoms

The clinical timeline matters for PI cases. CRPS symptoms typically emerge weeks to months after the initial injury -- not immediately. This delay is medically expected and well-documented in the literature. Defense teams sometimes argue that the delayed onset suggests the condition is unrelated to the accident; treating physicians and expert witnesses counter with the established natural history of CRPS development.

The CRPS Medication Protocol

CRPS requires a complex, multi-mechanistic medication approach. No single agent is sufficient, and the medication protocol must address neuropathic pain sensitization, autonomic dysregulation, and often psychological sequelae. Many CRPS medications are used off-label, which is one reason insurance coverage is frequently denied.

Gabapentin and Pregabalin

Gabapentinoids are the foundation of CRPS pharmacotherapy. They address central sensitization by reducing excitatory neurotransmitter release in the dorsal horn. Gabapentin is typically initiated at 300 mg three times daily and titrated to 1,800-3,600 mg/day. Pregabalin, with its linear absorption and faster onset, is preferred when rapid response is needed or when gabapentin has been inadequate. At the high doses often required for CRPS, both medications are expensive and frequently require prior authorization -- which health insurers often deny.

Tricyclic Antidepressants: Nortriptyline and Amitriptyline

Nortriptyline (25-75 mg at bedtime) and amitriptyline (10-50 mg at bedtime) are tricyclic antidepressants used for their neuropathic pain properties -- not for their antidepressant effect. They inhibit the reuptake of serotonin and norepinephrine at the spinal cord level, modulating descending pain inhibitory pathways. They also provide sedation that helps with the severe sleep disruption that CRPS patients experience. Nortriptyline is generally preferred over amitriptyline due to a more favorable side-effect profile.

Low-Dose Naltrexone (LDN)

Low-dose naltrexone (1.5-4.5 mg nightly) is an emerging treatment for CRPS and other chronic inflammatory pain conditions. At these low doses (far below the addiction-treatment doses of 50 mg), naltrexone acts as an antagonist at toll-like receptor 4 (TLR4) on microglia, reducing neuroinflammation. LDN is not FDA-approved for CRPS and must be compounded by a specialty pharmacy -- making it almost universally denied by standard health insurance. It is a medication that pharmacy liens routinely cover when prescribed by pain management specialists.

Ketamine

Ketamine is an NMDA receptor antagonist that blocks central sensitization at the dorsal horn level -- the neurological mechanism that perpetuates CRPS pain even in the absence of ongoing peripheral injury. In CRPS treatment, ketamine is used in two forms:

• Topical compounded ketamine cream applied directly to the affected extremity provides localized NMDA receptor antagonism without significant systemic absorption
• Intravenous ketamine infusions administered in pain clinic or anesthesiology settings provide systemic NMDA blockade for severe, refractory CRPS

Topical ketamine compounding is a pharmacy service. The compounded cream prescriptions are filled by a lien pharmacy and documented in the POGOS.

Bisphosphonates

Alendronate and other bisphosphonates have demonstrated efficacy in clinical trials for CRPS, likely through their anti-osteoclast and anti-inflammatory effects on bone. They are prescribed for CRPS patients with bone involvement (documented by triple-phase bone scan or MRI showing bone marrow edema) and are often covered under pharmacy liens when health insurance denies them as off-label for CRPS.

Topical Compounded Agents

Beyond ketamine, CRPS patients frequently receive compounded topical preparations combining multiple agents for localized effect: lidocaine 5% for local anesthesia, gabapentin 6% for local calcium channel modulation, clonidine 0.2% for sympathetic modulation, and ketamine 10% for NMDA blockade -- all in a single transdermal base applied to the affected limb. These multi-agent compounded creams represent some of the highest-value prescriptions in pharmacy lien practice and are almost always denied by standard health insurance.

Why Insurance Denies CRPS Medications

CRPS medications face systematic denial from standard health insurance for several reasons:

Off-label use: Most CRPS pharmacotherapy is off-label. Gabapentin and pregabalin are FDA-approved for postherpetic neuralgia and diabetic neuropathy, not CRPS specifically. LDN is not FDA-approved for any pain indication. Bisphosphonates are FDA-approved for osteoporosis. Insurers use off-label status as a basis for denial.

Compounding: Compounded medications are not FDA-approved products by definition. Most health plans exclude compounded medications from coverage entirely.

Experimental classification: Some plans classify ketamine infusions and LDN as experimental treatments and exclude them under experimental treatment exclusion clauses.

Prior authorization burdens: For medications that are technically covered, prior authorization requirements create delays and denials that interrupt treatment.

The result is that CRPS patients -- who have some of the most severe pain and the most medication-intensive treatment needs of any PI population -- are among those most likely to be denied the medications they need by their health insurance. This is precisely where pharmacy liens fill a critical gap.

How a Pharmacy Lien Covers CRPS Medications

A pharmacy lien covers compounded topicals, gabapentinoids, tricyclic antidepressants, bisphosphonates, and LDN at zero upfront cost to the patient. The lien attaches to the PI settlement and is paid at case resolution. For CRPS patients, the pharmacy lien is often not supplemental to health insurance -- it is the primary medication access mechanism throughout the case.

The POGOS in a CRPS case is particularly compelling. It shows:

• Long-duration medication management (often 24+ months)
• A complex, multi-agent regimen reflecting the severity and treatment-resistance of the condition
• Documented transitions and escalations (e.g., gabapentin to pregabalin, addition of LDN, addition of topical ketamine) that demonstrate clinical progression
• Diagnosis codes for CRPS Type I or II on every fill record

Related Resources

• Low-Dose Naltrexone for Chronic Pain After an Accident
• Compound Medications in Personal Injury Cases
• Gabapentin vs. Pregabalin for Nerve Pain After an Accident
• Nortriptyline for Chronic Pain After an Accident
• Specialty Medications in Personal Injury Cases